Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

Monday, November 13, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Efzofitimod, developed by aTyr Pharma, is a first-in-class immunomodulator targeting NRP2. It has shown effectiveness in preclinical models for treating rheumatoid arthritis and associated lung fibrosis. This innovative approach may provide new therapeutic options for patients suffering from these conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Efzofitimod shows promise as a first-in-class treatment.
  • Demonstrated efficacy in ameliorating rheumatoid arthritis.
  • Potential benefits for associated lung fibrosis in preclinical models.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is Efzofitimod?

Efzofitimod is a first-in-class immunomodulator targeting NRP2.

What conditions does Efzofitimod aim to treat?

It aims to treat rheumatoid arthritis and associated lung fibrosis.

What were the results of the preclinical studies?

Preclinical studies showed that Efzofitimod effectively ameliorates rheumatoid arthritis.

Who developed Efzofitimod?

Efzofitimod was developed by aTyr Pharma.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare Efzofitimod NRP2 rheumatoid arthritis lung fibrosis aTyr Pharma
Last updated: Nov 13, 2023

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →